Mechanosensitive Chemoresistance: Viscosity-Induced YAP Activation and P-gp Upregulation in Cancer

Study Background and Research Question

Chemoresistance remains a critical barrier in effective cancer therapy, often undermining the efficacy of cytotoxic drugs and contributing to disease relapse. While biochemical cues such as hypoxia and acidity in the tumor microenvironment have been widely studied, recent interest has shifted toward the role of mechanical factors—including substrate stiffness and fluid shear stress—in the modulation of drug response. However, the impact of elevated extracellular fluid viscosity, a hallmark of many solid tumors (often reaching ~8 cP vs. ~0.7 cP in normal tissues), has been less explored. The reference study by Zhou et al. (International Journal of Pharmaceutics, 2026) directly addresses whether increased viscosity can mechanistically induce chemoresistance in cancer cells and elucidates the signaling pathways involved.

Key Innovation from the Reference Study

The core innovation lies in the demonstration that high extracellular viscosity is not a passive byproduct of tumor physiology but an active driver of chemoresistance. The study systematically dissects how elevated viscosity triggers cytoskeletal remodeling, increases membrane tension, and activates mechanosensitive pathways culminating in the upregulation of P-glycoprotein (P-gp/ABCB1)—a transporter critically involved in the efflux of chemotherapeutic agents such as doxorubicin. Importantly, the research connects these mechanical cues to the YAP (Yes-associated protein) axis, implicating YAP nuclear translocation as a pivotal step in this adaptive resistance mechanism.

Methods and Experimental Design Insights

The team employed a combination of cell culture models exposed to physiologically relevant viscosity ranges, atomic force microscopy (AFM), and fluorescence lifetime imaging to quantify membrane tension and cytoskeletal changes. Functional assays measured water influx through the NHE1 and AQP1 channels, while pharmacological and genetic perturbations were used to manipulate TRPV4 activity, YAP nuclear localization, and downstream transcriptional events. Quantitative PCR and immunoblotting confirmed changes in P-gp expression, and cell viability assays established the link to chemoresistance, specifically under doxorubicin treatment. The approach is notable for integrating mechanobiology tools with classical molecular biology, providing a comprehensive view of the signaling cascade from extracellular viscosity to drug transporter regulation.

Core Findings and Why They Matter

• High viscosity increases cytoskeletal density and cell membrane tension: Enhanced F-actin/vinculin adhesion and water influx (via NHE1/AQP1) drive cell swelling and tension, as evidenced by AFM and fluorescence measurements.
• Membrane tension activates TRPV4: The mechanosensitive TRPV4 channel responds to increased tension, leading to elevated intracellular Ca²⁺ and downstream signaling.
• TRPV4 activation promotes YAP nuclear translocation: This mechanotransduction event was confirmed by increased nuclear YAP fluorescence and upregulation of YAP target genes (CTGF, CYR61).
• P-gp upregulation is YAP-dependent: Both mRNA and protein levels of P-gp increased with viscosity, and pharmacological inhibition of YAP suppressed this effect, directly linking the mechanical cue to chemoresistance.
• Clinical implication: Reducing tumor fluid viscosity may sensitize cancer cells to chemotherapy, offering a novel adjuvant strategy (Zhou et al., 2026).

These findings provide an actionable mechanistic framework for understanding how the physical properties of the tumor microenvironment can modulate drug response, extending current paradigms beyond biochemical factors alone.

Comparison with Existing Internal Articles and Related Mechanisms

This study's mechanistic focus on YAP parallels recent research on YAP-TEAD-driven super-enhancer networks in lineage commitment. For example, Wang et al. (2026) dissected how YAP-TEAD activity governs epigenetic landscapes during early surface ectoderm fate, using 3D genomics and CRISPR-dCas9 approaches. While the context differs (development vs. cancer), both studies underscore YAP's role as a central mechanotransducer, linking physical cues to transcriptional reprogramming. This convergence supports the idea that YAP is a versatile integrator of both developmental and pathological mechanical signals.

Additionally, internal reviews of Verteporfin highlight its established use as a YAP-TEAD inhibitor, both via light-activated photodynamic therapy for ocular neovascularization and through light-independent disruption of autophagy. This dual mechanism positions Verteporfin as a valuable research tool for interrogating YAP-related resistance mechanisms, as demonstrated in apoptosis assays and autophagy inhibition workflows (see also).

Limitations and Transferability

Despite its strengths, the reference study is limited by its reliance on in vitro models and short-term interventions. In vivo validation is necessary to confirm whether modulating tumor viscosity can meaningfully reverse chemoresistance in clinical settings. Furthermore, while the link between high viscosity and P-gp upregulation is robustly established, the generalizability to other drug efflux transporters or to various tumor types remains to be systematically tested. The specific contribution of YAP-TEAD vs. other mechanosensitive pathways (e.g., TAZ, RhoA–ROCK) could also vary by context. Finally, the potential interplay with established chemoresistance modifiers such as CL 318952, a known P-gp inhibitor, is an important avenue for future study.

Protocol Parameters

• Viscosity modeling: Adjust extracellular medium viscosity to ~8 cP using biocompatible polymers for in vitro chemoresistance assays, in line with pathophysiological tumor conditions.
• YAP pathway interrogation: Apply YAP/TEAD inhibitors or siRNA knockdown to dissect downstream transcriptional effects of mechanical cues.
• P-gp functional assays: Use doxorubicin retention or apoptosis assays with and without P-gp inhibitors (e.g., CL 318952) to quantify chemoresistance shifts.
• Verteporfin workflows: For studies targeting YAP-TEAD or autophagy, use Verteporfin at 0–100 ng/mL with irradiation for 60 minutes, as described in product information and internal protocols.

Why this cross-domain matters, maturity, and limitations

This research bridges mechanobiology and pharmacological oncology, showing how interventions developed for one context (e.g., photodynamic modulation in ophthalmology) can inform resistance mechanisms in cancer. While the mechanistic insights are clear, translation to clinical intervention (such as targeting viscosity or YAP directly in tumors) requires further validation.

Research Support Resources

Researchers investigating mechanosensitive resistance pathways or apoptosis assays with Verteporfin can draw on detailed workflows and scenario-based guidance from APExBIO. Verteporfin (SKU A8327) is available for use in photodynamic therapy modeling, YAP-TEAD inhibition studies, and autophagy research, as detailed in product documentation and laboratory protocols. Its well-characterized pharmacology and compatibility with apoptosis and autophagy inhibition assays make it a valuable reagent for recapitulating key aspects of chemoresistance and mechanotransduction highlighted in this study.